MARKET

LUCD

LUCD

Lucid Diagnostics Inc.
NASDAQ
1.280
+0.060
+4.92%
After Hours: 1.300 +0.02 +1.56% 19:59 01/27 EST
OPEN
1.240
PREV CLOSE
1.220
HIGH
1.280
LOW
1.220
VOLUME
140.90K
TURNOVER
0
52 WEEK HIGH
4.060
52 WEEK LOW
1.105
MARKET CAP
50.06M
P/E (TTM)
-0.8303
1D
5D
1M
3M
1Y
5Y
Why PAVmed Shares Are Falling Today
Benzinga · 01/18 19:18
TC Biopharm, G Medical top healthcare gainers; Lucid, Hyperfine among losers
Seeking Alpha · 01/18 15:00
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
Benzinga · 01/18 11:24
Needham Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
TipRanks · 01/18 11:05
PAVmed, its units Lucid Diagnostics, Veris Health implement strategic changes, layoffs
Seeking Alpha · 01/17 21:40
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/17 21:31
PAVmed, Subsidiaries to Cut 20% of Jobs, Streamline Product Portfolio to Reduce Quarterly Cash Burn
PAVmed, Subsidiaries to Cut 20% of Jobs, Streamline Product Portfolio to Reduce Quarterly Cash Burn
MT Newswires · 01/17 16:46
Catalyst watch: Eyes on Virgin Galactic, Monster Beverage, Procter & Gamble and Netflix
Seeking Alpha · 01/13 20:00
More
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. It is also developing EsoCure, which is an esophageal ablation device to treat dysplastic barretts esophagus (BE) before it can progress to EAC.

Webull offers kinds of Lucid Diagnostics Inc stock information, including NASDAQ:LUCD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUCD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LUCD stock methods without spending real money on the virtual paper trading platform.